Abstract
Seborrhoeic dermatitis is common in children and Malassezia species play an important role in its pathogenesis. Infants present with yellow scales on the scalp and erythematous, eczematous skin affecting the flexures. The incidence declines after one year of age. Differential diagnoses include atopic dermatitis, psoriasis, tinea capitis, candidiasis and Langerhans cell histiocytosis. Antifungal shampoos or creams, sometimes in combination with mild potency topical steroids are effective treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Sonea MJ, Moroz BE, Reece ER. Leiner’s disease associated with diminished third component of complement. Pediatr Dermatol. 1987;4:105–7.
Schachner L, Ling NS, Press S. A statistical analysis of a pediatric dermatology clinic. Pediatr Dermatol. 1983;1:157–64.
Foley P, Zuo Y, Plunkett A, Merlin K, Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003;139:318–22.
Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson Jr TL. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004;51:785–98.
Williams JV, Eichenfield LF, Burke BL, Barnes-Eley M, Friedlander SF. Prevalence of scalp scaling in prepubertal children. Pediatrics. 2005;115:e1–6.
Neville E, Finn O. Psoriasiform napkin dermatitis – a follow-up study. Br J Dermatol. 1975;92:279–85.
Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. 1999;14:512–7.
Hubbard TW. The predictive value of symptoms in diagnosing childhood tinea capitis. Arch Pediatr Adolesc Med. 1999;153:1150–3.
Coley MK, Bhanusali DG, Silverberg JI, Alexis AF, Silverberg NB. Scalp hyperkeratosis and alopecia in children of color. J Drugs Dermatol. 2011;10:511–6.
Menni S, Piccino R, Baietta S, Ciuffreda A, Scotti L. Infantile seborrheic dermatitis: seven-year follow-up and some prognostic criteria. Pediatr Dermatol. 1989;6:13–5.
Mimouni K, Mikamel M, Zeharia A, Mimouni M. Prognosis of infantile seborrheic dermatitis. J Pediatr. 1995;127:744–6.
Podmore P, Burrows D, Eedy D, Stanford C. Seborrheic eczema a disease entity or a clinical variant of atopic eczema? Br J Dermatol. 1986;115:341–50.
Beare J, Rook AJ. Infantile seborrhoeic dermatitis. In: Rook AJ, Wilkinson DS, Ebling FJ, editors. Textbook of dermatology. Oxford: Blackwell; 2012. p. 17.28–30.
Moises-Alfaro CB, Caceres-Rios HW, Rueda M, Velazquez-Acosta A, Ruiz-Maldonado R. Are infantile seborrheic and atopic dermatitis clinical variants of the same disease? Int J Dermatol. 2002;41:349–51.
Ng SS, Koh MJ, Tay YK. Cutaneous Langerhans cell histiocytosis: study of Asian children shows good overall prognosis. Acta Paediatr. 2013;102:e514–8.
Ran Y, Yoshiike T, Ogawa H. Lipase of Malassezia furfur: some properties and their relationship to cell growth. J Med Vet Mycol. 1993;3:77–85.
Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabolism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp Proc. 2005;10:194–7.
Tajima M, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol. 2008;128:345–51.
Zaidi Z, Wahid Z, Cochinwala R, Soomro M, Qureishi A. Correlation of the density of yeast Malassezia with the clinical severity of seborrhoeic dermatitis. J Pak Med Assoc. 2002;52:504–6.
Gupta AK, Nicol K, Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004;5:417–22.
Zhang H, Ran Y, Xie Z, Zhang R. Identification of Malassezia species in patients with seborrheic dermatitis in China. Mycopathologia. 2013;175:83–9.
Nakabayashi A, Sei Y. Relationship between Malassezia Yeast and Infantile Seborrhoeic Dermatitis. Nippon Ishinkin Gakkai Zasshi. 2001;42:218–20.
Broberg A, Faergemann J. Infantile seborrhoeic dermatitis and Pityrosporum ovale. Br J Dermatol. 1989;120:359–62.
Ahtonen P, Lehtonen OP, Kero P, Tunnela E, Havu V. Malassezia furfur colonization of neonates in an intensive care unit. Mycoses. 1990;33:543–7.
Shattuck KE, Cochran CK, Zabransky RJ, Pasarell L, Davis JC, Malloy MH. Colonization and infection associated with Malassezia and Candida species in a neonatal unit. J Hosp Infect. 1996;34:123–39.
Tollesson A, Frithz A, Berg A, Karlman G. Essential fatty acids in infantile seborrheic dermatitis. J Am Acad Dermatol. 1993;28:957–61.
Zeharia A, Mimouni M, Fogel D. Treatment with bifonazole shampoo for scalp seborrhoea in infants and young children. Paediatr Dermatol. 1996;13:151–3.
Brodell R, Patel S, Venglarick J, Moses D, Gemmel D. Safety of ketoconazole shampoo for infantile seborrheic dermatitis. Pediatr Dermatol. 1988;15:406–7.
Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology. 1992;184:275–80.
Katsambas A, Antoniou C, Frangouli E, Avgerinou G, Michailidis D, Stratigos J. A double-blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br J Dermatol. 1989;121:353–7.
Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993;29:1008–12.
Pari T, Pulimood S, Jacob M, George S, Jeyaseelan L, Thomas K. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol. 1988;10:89–90.
Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol. 1986;114:695–700.
Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients. J Korean Med Sci. 2007;22:868–72.
Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004;151:1071–5.
Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatol Treat. 2009;20:4–9.
Firooz A, Solhpour A, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, Rashighi-Firoozabadi M, Dowlati Y. Pimecrolimus cream, 1%, vs. hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142:1065–86.
Rallis E, Naiopoulou A, Kouskoukis C, et al. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004;30:191–5.
Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 2003;49:145–7.
Braza TJ, DiCarlo JB, Soon SL, McCall CO. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol. 2003;148:1242–4.
Yoon TY, Kim HJ, Kim MK. Pimecrolimus-induced rosacea-like demodicidosis. Int J Dermatol. 2007;46:1103–5.
Cunha PR. Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol. 2006;86:69–70.
Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205:271–7.
Langley RG, Eichenfield LF, Lucky AW, Boguniewicz M, Barbier N, Cherill R. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol. 2008;25:301–7.
Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495–504.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Teoh, YL., Tay, YK. (2015). Seborrhoeic Dermatitis in Children. In: Silverberg, N., Durán-McKinster, C., Tay, YK. (eds) Pediatric Skin of Color. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6654-3_31
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6654-3_31
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6653-6
Online ISBN: 978-1-4614-6654-3
eBook Packages: MedicineMedicine (R0)